New vaccine trial targets aggressive brain cancer
NCT ID NCT05283109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a vaccine made from small protein pieces (peptides) designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. The study includes 24 adults with newly diagnosed, untreated glioblastoma that has a specific genetic marker. The main goal is to check the vaccine's safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Preston Robert Tisch Brain Tumor Center at Duke University
Durham, North Carolina, 27710, United States